Global Health Limited — Annual Report FY2026
Quality Scores
AI Summary
Global Health Limited (Medanta) has established itself as a premier multi-specialty tertiary care provider in North and East India, demonstrating a significant turnaround from FY21 onwards. The company operates 3,435 installed beds across 6 hospitals, with a specialty focus on high-complexity clinical disciplines. Revenue has grown at a 25% CAGR over the last 5 years, while trailing profits have surged at 81% CAGR due to operating leverage and improving occupancy. The business profile is characterized by high Average Revenue Per Occupied Bed (ARPOB) and a premium clinical talent pool. Current…
Key Changes
Medanta has evolved from a single-flagship specialty center in Gurugram (established 2009) into a multi-city tertiary healthcare network. The evolution is marked by a shift towards a hub-and-spoke model and expansion into underserved regions like Bihar (Patna) and Uttar Pradesh (Lucknow, Noida). The clinical profile has deepened into high-acuity specialties including organ transplants and robotic surgeries, which command higher Average Revenue Per Occupied Bed (ARPOB). Between 2016 and 2026, the company nearly tripled its revenue from ₹1,382 Cr to ₹4,410 Cr, demonstrating a successful scaling of the Medanta brand. Digital transformation initiatives via the 'Medanta eClinic' and lab expansion signify a move towards an integrated healthcare ecosystem. The business is successfully moving up…
Management Commentary
Led by Dr. Naresh Trehan, a globally renowned cardiac surgeon, the leadership combines high-level clinical excellence with professional corporate management. The vision centers on 'cluster-based' dominance, ensuring Medanta remains the primary referral center for complex cases. MD&A commentary is consistently transparent regarding expansion timelines and clinical outcome benchmarks. There is a clear focus on digital transformation and home care to extend the hospital ecosystem. Management has successfully navigated the transition from a private-equity-backed entity to a listed corporation without significant governance friction.
Financial Highlights
The financial trajectory of Medanta shows a clear inflection point in FY22, where margins expanded from mid-teens to over 20%. Revenue grew from ₹1,447 Cr in FY21 to ₹4,410 Cr (Expected 2026), driven by the scaling of the Lucknow and Patna units. EBITDA margins reached a peak of 25% in FY24 before cooling slightly due to new expansion costs in Noida and Lucknow phase II. Return on Equity (ROE) has stabilized at 15-16% following the IPO-led deleveraging. Interest coverage remains healthy as the company utilizes internal accruals to fund brownfield expansions.
Major Opportunities
- Exceptional 5-year PAT CAGR of 81%
- Consistent negative Cash Conversion Cycle
- Robust ROCE of 17-20%
Major Risks
- Stock price trading at expensive 8.5x Book Value
- Heavy concentration in North and East India
- Recent margin contraction in FY26 projections
Unlock the full report
Full 20+ sections, charts, AI chat with the report, and PDF export are available with Premium.